Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04939142 is registered in ClinicalTrials.gov with Antengene Corporation as lead sponsor.

NCT NCT04939142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04939142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Antengene Corporation
Phase
Phase 3
Overall status
Completed
Start date
July 12, 2021
Completion date
October 30, 2025
Enrollment
154 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma